Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trial

Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trial

Submitted by admin on May 7, 2024 - 11:14am
Source: 
Fierce Biotech
News Tags: 
Vertex Pharmaceuticals
cystic fibrosis
Vanza Triple
FDA
gene therapy
Headline: 
Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trial
snippet: 

Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple.

Vertex completed the regulatory submission a month before its goal of mid-2024, CEO Reshma Kewalramani, M.D., said on a first-quarter earnings call May 6.

Do Not Allow Advertisers to Use My Personal information